Victoria Smith

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

Vivian Barry-Hamilton, Rhyannon Spangler, Derek Marshall et al. · Nature Medicine · 2010 · 841 citations

Redox Signaling, Allosteric Inhibition, Lysyl Oxidase–like-2 Impedes +7

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Naoki Ikenaga, Zhenwei Peng, Kahini A. Vaid et al. · Gut · 2017 · 291 citations · Full text

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

Ganesh Raghu, Kevin M. Brown, Harold R. Collard et al. · The Lancet Respiratory Medicine · 2016 · 271 citations

Simtuzumab Versus Placebo, Idiopathic Pulmonary Fibrosis, Pulmonary Pharmacology +5

Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

Jin Yang, Konstantinos Savvatis, Jong Seok Kang et al. · Nature Communications · 2016 · 261 citations · Full text

Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice

Susan B. Liu, Naoki Ikenaga, Zhenwei Peng et al. · The FASEB Journal · 2015 · 214 citations